Quick Answer
Dare Bioscience, Inc. reported Total Revenue of $1.03 million for the year ending 2025.
- Dare Bioscience, Inc. showed an increase of +10,429.4% in Total Revenue from 2024 to 2025.
- This data is from Dare Bioscience, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2012 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2013: $6.0 thousand | Q1 2014: $47.0 thousand | Q2 2014: $33.0 thousand | Q1 2015: $0.00 | Q4 2016: $766.0 thousand | Q1 2017: $1.19 million | Q2 2017: $642.0 thousand | Q2 2021: $0.00 | Q2 2021: $0.00 | Q3 2021: $0.00 | Q3 2021: $0.00 | Q2 2022: $10.00 million | Q2 2022: $10.00 million | Q3 2022: $0.00 | Q3 2022: $0.00 | Q1 2023: $0.00 | Q1 2023: $0.00 | Q2 2023: $0.00 | Q2 2023: $0.00 | Q3 2023: $1.00 million | Q3 2023: $1.00 million | Q1 2024: $9.3 thousand | Q1 2024: $9.3 thousand | Q2 2024: $22.4 thousand | Q2 2024: $22.4 thousand | Q3 2024: $41.7 thousand | Q3 2024: $41.7 thousand | Q1 2025: $25.4 thousand | Q3 2025: $2.3 thousand.
- Over the full 12 years of available data (2012 to 2025), Dare Bioscience, Inc.'s Total Revenue has grown by 64.8%.
- Historical annual values: Fiscal year 2025: $1.03 million | Fiscal year 2024: $9.8 thousand | Fiscal year 2023: $2.81 million | Fiscal year 2023: $2.81 million | Fiscal year 2022: $10.00 million | Fiscal year 2022: $10.00 million | Fiscal year 2021: $0.00 | Fiscal year 2021: $0.00 | Fiscal year 2016: $766.0 thousand | Fiscal year 2014: $80.0 thousand | Fiscal year 2013: $6.0 thousand | Fiscal year 2012: $625.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: